Results 141 to 150 of about 168,682 (384)

Osteoblast‐CD4+ CTL Crosstalk Mediated by SIRT1/DAAM2 Axis Prevents Age‐Related Bone Loss

open access: yesAdvanced Science, EarlyView.
In the osteoblastic niche, SIRT1 activates and recruits CD4+ CTLs by increasing DAAM2 expression via EZH2 deacetylation and boosting the secretion of key chemokines, such as CCL3, CCL5, and CXCL10. Then, CD4+ CTL directly eliminates senescent osteoblasts in an MHC‐II‐dependent way, thereby slowing down the process of bone ageing and effectively ...
Bin Yang   +20 more
wiley   +1 more source

Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. [PDF]

open access: yes, 2008
Systemic mastocytoses represent neoplastic proliferations of mast cells. In about 20% of cases systemic mastocytoses are accompanied by clonal haematopoietic non-mast cell-lineage disorders, most commonly myeloid neoplasms.
Dirnhofer, S.   +7 more
core   +1 more source

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies

open access: yesClinical Cancer Research, 2018
Purpose: Despite promising clinical activity, T-cell–engaging therapies including T-cell bispecific antibodies (TCB) are associated with severe side effects requiring the use of step-up-dosing (SUD) regimens to mitigate safety.
M. Bacac   +22 more
semanticscholar   +1 more source

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden

open access: yesHaematologica, 2011
Background CD20 monoclonal antibodies are widely used in clinical practice. Antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and direct cell death have been suggested to be important effector functions for CD20 antibodies ...
Peter Boross   +10 more
doaj   +1 more source

Critical Role of IL1R2‐ENO1 Interaction in Inhibiting Glycolysis‐Mediated Pyroptosis for Protection Against Lethal Sepsis

open access: yesAdvanced Science, EarlyView.
The authors have discovered that intracellular interleukin 1 receptor 2 (IL1R2) negatively regulates pyroptosis and inflammation by inhibiting glycolysis in sepsis. Soluble IL1R2 is released from macrophages undergoing pyroptosis. IL1R2 acts as a novel negative regulator of glycolysis by interacting with enolase 1 (ENO1), thereby inhibiting gasdermin D
Chuyi Tan   +13 more
wiley   +1 more source

Advancements in DNA‐Driven Precision Modulation of Cell Surface Receptor for Programmable Cellular Functions

open access: yesAdvanced Science, EarlyView.
DNA‐Based Genetic and Non‐Genetic Tools for Receptor Engineering. This review highlights recent advances in DNA‐based strategies for receptor engineering, including genetic approaches like domain fusion and site‐directed mutagenesis, as well as non‐genetic methods using functional nucleic acids, DNA nanostructures, and dynamic DNA reactions.
Hexin Nan   +4 more
wiley   +1 more source

Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects [PDF]

open access: yes, 2017
A growing body of studies highlights involvement of neutrophils in cancer development and progression. Our aim was to assess the phenotypic and functional properties of circulating neutrophils from patients with chronic lymphocytic leukemia (CLL).
Gabčová, Gabriela   +10 more
core   +1 more source

Mycosis Fungoides, Sézary Syndrome, and Cutaneous B‐Cell Lymphomas: 2025 Update on Diagnosis, Risk‐Stratification, and Management

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Disease Overview Primary cutaneous lymphomas are a rare and heterogeneous group of extranodal lymphomas that require the integration of clinical and histopathologic data for classification and treatment. Diagnosis Diagnosis and disease classification is based on histopathologic review and immunohistochemical staining of an appropriate skin ...
Alexandra C. Hristov   +2 more
wiley   +1 more source

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. [PDF]

open access: yes, 2009
The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in targeting the pathogenesis for these diseases, patients experience significantly fewer side effects ...
Sands, Jacob, Tuscano, Joseph M
core   +2 more sources

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.

open access: yesThe Lancet Haematology, 2022
R. Bannerji   +18 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy